XML 142 R31.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Earnings Per Share (Tables) | 3 Months Ended
--- | ---
Dec. 31, 2023
Earnings Per Share [Abstract] |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the computation of basic and diluted earnings per share for the three months ended December 31, 2023 and 2022.
|  |  |  | Three Months Ended December 31,
|  |  |  |  |  | 2023 |  | 2022
|  |  |  |  |  | (in thousands, except per share amounts)
Numerator: |  |  |  |  |  |  |  |
Net loss attributable to Arrowhead Pharmaceuticals, Inc. |  |  |  |  |  | $ | (132,864) |  |  | $ | (41,325) |
Denominator: |  |  |  |  |  |  |  |
Weighted-average basic shares outstanding |  |  |  |  |  | 107,415 |  |  | 106,039 |
Effect of dilutive securities |  |  |  |  |  | — |  |  | — |
Weighted-average diluted shares outstanding |  |  |  |  |  | 107,415 |  |  | 106,039 |
Basic earnings per share |  |  |  |  |  | $ | (1.24) |  |  | $ | (0.39) |
Diluted earnings per share |  |  |  |  |  | $ | (1.24) |  |  | $ | (0.39) |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration